Neurocrine biosciences presents data on improvements in physiologic glucocorticoid dosing and select reproductive hormones in patients with classic congenital adrenal hyperplasia taking crenessity™ (crinecerfont)

90% of pediatric participants on crenessity versus 21% on placebo achieved ≥1 threshold for androstenedione reduction or glucocorticoid reduction observed rates of select reproductive hormone normalization in adult males taking crenessity with substantial glucocorticoid dose reductions findings presented at the 2025 american association of clinical endocrinology annual meeting san diego , may 15, 2025 /prnewswire/ -- neurocrine biosciences, inc.  (nasdaq: nbix) today announced new data from the phase 3 cahtalyst™ adult and pediatric studies of crenessity™ (crinecerfont). the data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels.
NBIX Ratings Summary
NBIX Quant Ranking